港股异动 | 宜明昂科-B(01541)拉升逾16% 阿沐瑞芙普α皮下制剂IMM0306S治疗系统性红斑狼疮IND获批

智通财经03-06

智通财经APP获悉，宜明昂科-B(01541)拉升逾16%，截至发稿，涨15.87%，报4.38港元，成交额947.17万港元。消息面上，3月4日，据宜明昂科官微消息，公司宣布，自主研发的阿沐瑞芙普α皮下注射制剂(IMM0306S)，用于治疗系统性红斑狼疮(SLE)的临床试验申请(IND)已获得中国国家药品监督管理局(NMPA)的正式批准。这一里程碑式的进展标志着宜明昂科在自身免疫性疾病领域的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2617509266?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-06 11:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617509266","market":"fut","top_or_hot":-1,"title":"港股异动 | 宜明昂科-B(01541)拉升逾16% 阿沐瑞芙普α皮下制剂IMM0306S治疗系统性红斑狼疮IND获批","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)拉升逾16%，截至发稿，涨15.87%，报4.38港元，成交额947.17万港元。消息面上，3月4日，据宜明昂科官微消息，公司宣布，自主研发的阿沐瑞芙普α皮下注射制剂(IMM0306S)，用于治疗系统性红斑狼疮(SLE)的临床试验申请(IND)已获得中国国家药品监督管理局(NMPA)的正式批准。这一里程碑式的进展标志着宜明昂科在自身免疫性疾病领域的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410853.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B(01541)拉升逾16% 阿沐瑞芙普α皮下制剂IMM0306S治疗系统性红斑狼疮IND获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B(01541)拉升逾16% 阿沐瑞芙普α皮下制剂IMM0306S治疗系统性红斑狼疮IND获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-06 11:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1410853.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)拉升逾16%，截至发稿，涨15.87%，报4.38港元，成交额947.17万港元。消息面上，3月4日，据宜明昂科官微消息，公司宣布，自主研发的阿沐瑞芙普α皮下注射制剂(IMM0306S)，用于治疗系统性红斑狼疮(SLE)的临床试验申请(IND)已获得中国国家药品监督管理局(NMPA)的正式批准。这一里程碑式的进展标志着宜明昂科在自身免疫性疾病领域的创新...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410853.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1410853.html","article_id":"2617509266","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617509266","pubTimestamp":1772768845,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，宜明昂科-B拉升逾16%，截至发稿，涨15.87%，报4.38港元，成交额947.17万港元。消息面上，3月4日，据宜明昂科官微消息，公司宣布，自主研发的阿沐瑞芙普α皮下注射制剂，用于治疗系统性红斑狼疮的临床试验申请已获得中国国家药品监督管理局的正式批准。此次阿沐瑞芙普α皮下注射制剂治疗系统性红斑狼疮的IND获批，是宜明昂科在自身免疫性疾病领域密集布局的最新成果，也是其“自免管线全面开花”战略的重要体现。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","IND":"Xtrackers Nifty 500 India ETF","VT":"世界全股市ETF-Vanguard","VXUS":"国际股票ETF-Vanguard","01541":"宜明昂科-B"},"translate_title":"Changes in Hong Kong stocks | Yiming Angke-B (01541) rose by more than 16%. Amurifupu α subcutaneous preparation IMM0306S was approved for the treatment of systemic lupus erythematosus IND","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1.5,"VT":1.5,"VXUS":1.5,"IND":1.5},"content_text":"智通财经APP获悉，宜明昂科-B(01541)拉升逾16%，截至发稿，涨15.87%，报4.38港元，成交额947.17万港元。消息面上，3月4日，据宜明昂科官微消息，公司宣布，自主研发的阿沐瑞芙普α皮下注射制剂(IMM0306S)，用于治疗系统性红斑狼疮(SLE)的临床试验申请(IND)已获得中国国家药品监督管理局(NMPA)的正式批准。这一里程碑式的进展标志着宜明昂科在自身免疫性疾病领域的创新药物研发取得了重大突破。此次阿沐瑞芙普α皮下注射制剂(IMM0306S)治疗系统性红斑狼疮(SLE)的IND获批，是宜明昂科在自身免疫性疾病领域密集布局的最新成果，也是其“自免管线全面开花”战略的重要体现。近年来，依托“mAb-Trap”技术平台，IMM0306已在多个重磅自免适应症中取得关键进展，构建了丰富且具深度的产品梯队。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617509266","isCrawlerRequest":true}